Assess the sensitivity, specificity, positive predictive value, and negative predictive value of dynamic monitoring of circulating tumor DNA (ctDNA) combined with circulating HPV DNA (cfHPV DNA) for early prediction of recurrence in cervical cancer post-surgery or post-treatment, and compare its advantages and disadvantages with existing diagnostic methods.
Patients with newly diagnosed HPV-positive cervical malignancy at stages I-IV who have not undergone surgery, radiation therapy, or chemotherapy.
Patients must be older than 18 years of age.
Cervical cancer patients who are eligible for surgery and/or chemoradiotherapy.
Estimated life expectancy of more than three months.
Patients who are participating in other clinical trials.
Pregnant or breastfeeding women.
Patients with severe mental illness.
Patients who voluntarily withdraw.
Patients with newly diagnosed HPV-positive cervical malignancy at stages I-IV who have not undergone surgery, radiation therapy, or chemotherapy.
Cohort
Prospective
Assess the risk of recurrence and the efficacy of medication
Diagnostic testEvaluation of recurrence risk and medication efficacy through liquid biopsy
sensitivity
true positive rate
Click on the lead sponsor to view all of their trials.
